However, recently, it has been reported that NR6A1 is lower expressed in ER+ and ER- breast cancer compared with normal mammary gland tissue, and low levels of NR6A1 in cancer cells exhibit higher sensitivity to the anticancer drug ecteinascidin[13]. This evidence concerns the gene NR6A1 and breast carcinoma.